Treprostinil

Treprostinil
Clinical data
Trade names	Remodulin, Orenitram, Tyvaso, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Treprostinil;
Pregnancy; category	AU: B3; ;
Routes of; administration	Subcutaneous, intravenous, inhalation, by mouth
ATC code	B01AC21 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~100%
Metabolism	Substantially metabolized by the liver
Elimination half-life	4 hours
Excretion	Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%)
Identifiers
	IUPAC name (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid;
CAS Number	81846-19-7 ;
PubChem CID	6918140;
IUPHAR/BPS	5820;
DrugBank	DB00374 ;
ChemSpider	5293353 ;
UNII	RUM6K67ESG;
KEGG	D06213 ; D08628 ;
ChEBI	CHEBI:50861 ;
ChEMBL	ChEMBL1201254 ;
CompTox Dashboard (EPA)	DTXSID901021654 ;
ECHA InfoCard	100.236.149
Chemical and physical data
Formula	C23H34O5
Molar mass	390.520 g·mol−1
	InChI InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1 ; Key:PAJMKGZZBBTTOY-ZFORQUDYSA-N ;
	(what is this?) (verify)

Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.^[6]

Treprostinil was approved for use in the United States in May 2002.^[7]

^ "Remodulin- treprostinil injection, solution; Sterile diluent for remodulin- water injection, solution". DailyMed. 9 October 2023. Retrieved 21 May 2024.
^ "Orenitram- treprostinil tablet, extended release; Orenitram- treprostinil kit". DailyMed. 7 November 2023. Retrieved 21 May 2024.
^ "Tyvaso- treprostinil inhalant". DailyMed. 8 December 2023. Retrieved 21 May 2024.
^ "Tyvaso DPI- treprostinil inhalant; Tyvaso DPI- treprostinil kit". DailyMed. 26 January 2024. Retrieved 21 May 2024.
^ Cite error: The named reference Trepulmix EPAR was invoked but never defined (see the help page).
^ Torres F, Rubin LJ (January 2013). "Treprostinil for the treatment of pulmonary arterial hypertension". Expert Review of Cardiovascular Therapy. 11 (1): 13–25. doi:10.1586/erc.12.160. PMID 23259441. S2CID 29661141.
^ "Drug Approval Package: Remodulin (Treprostinil Sodium) NDA #021272". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 9 April 2020.

[Remodulin_FDA_label-1] "Remodulin- treprostinil injection, solution; Sterile diluent for remodulin- water injection, solution". DailyMed. 9 October 2023. Retrieved 21 May 2024.

[Orenitram_FDA_label-2] "Orenitram- treprostinil tablet, extended release; Orenitram- treprostinil kit". DailyMed. 7 November 2023. Retrieved 21 May 2024.

[Tyvaso_FDA_label-3] "Tyvaso- treprostinil inhalant". DailyMed. 8 December 2023. Retrieved 21 May 2024.

[Tyvaso_DPI_FDA_label-4] "Tyvaso DPI- treprostinil inhalant; Tyvaso DPI- treprostinil kit". DailyMed. 26 January 2024. Retrieved 21 May 2024.

[Trepulmix_EPAR-5] Cite error: The named reference Trepulmix EPAR was invoked but never defined (see the help page).

[pmid23259441-6] Torres F, Rubin LJ (January 2013). "Treprostinil for the treatment of pulmonary arterial hypertension". Expert Review of Cardiovascular Therapy. 11 (1): 13–25. doi:10.1586/erc.12.160. PMID 23259441. S2CID 29661141.

[Remodulin_FDA_approval-7] "Drug Approval Package: Remodulin (Treprostinil Sodium) NDA #021272". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 9 April 2020.

[1]

[2]

[3]

[4]

[5]

[6]

[7]